Evidence map›Paper›PMID 32042192›Full record

ArticleNature medicine2020

Using human genetics to understand the disease impacts of testosterone in men and women.

Katherine S Ruth, Felix R Day, Jessica Tyrrell, Deborah J Thompson, Andrew R Wood, Anubha Mahajan, Robin N Beaumont, Laura Wittemans, Susan Martin, Alexander S Busch and 13 more

Open access · greenAbstract read
In one paragraph

Article in Nature medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 420 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
420citing papers in PubMed, 12 pooled it
69.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

420 citing papers in PubMed, 12 syntheses or guidelines pooled it, 743 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

360 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 3 countries.

Katherine S Ruth *University of Exeter Medical School, University of Exeter, Exeter, UK.
Felix R Day *Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-3789-7651
Jessica Tyrrell *University of Exeter Medical School, University of Exeter, Exeter, UK.
Deborah J Thompson *Centre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.
Andrew R WoodUniversity of Exeter Medical School, University of Exeter, Exeter, UK.
Anubha MahajanWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Robin N BeaumontUniversity of Exeter Medical School, University of Exeter, Exeter, UK.
Laura WittemansMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.
Susan MartinUniversity of Exeter Medical School, University of Exeter, Exeter, UK.ORCID http://orcid.org/0000-0001-8746-0947
Alexander S BuschMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-4417-569X
A Mesut ErzurumluogluMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-1322-8138
Benjamin HollisMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.
Tracy A O'MaraDepartment of Genetics, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia.ORCID http://orcid.org/0000-0002-5436-3232
Endometrial Cancer Association Consortium
Mark I McCarthyWellcome Centre for Human Genetics, University of Oxford, Oxford, UK.
Claudia LangenbergMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0002-5017-7344
Douglas F EastonCentre for Cancer Genetic Epidemiology, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0003-2444-3247
Nicholas J WarehamMedical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.
Stephen BurgessMRC Biostatistics Unit, University of Cambridge, Cambridge, UK.ORCID http://orcid.org/0000-0001-5365-8760
Anna Murray *University of Exeter Medical School, University of Exeter, Exeter, UK.
Ken K Ong *Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK.
Timothy M Frayling *University of Exeter Medical School, University of Exeter, Exeter, UK. T.M.Frayling@exeter.ac.uk.
John R B Perry *Medical Research Council (MRC) Epidemiology Unit, University of Cambridge, Cambridge, UK. john.perry@mrc-epid.cam.ac.uk.
University of Cambridge · GBUniversity of Exeter · GBCentre for Human Genetics · GBQIMR Berghofer Medical Research Institute · AUUniversity of Copenhagen · DK

Funding

Medical Research Council MC_PC_12028Medical Research Council MC_PC_17228Medical Research Council MC_QA137853Medical Research Council MC_UU_00002/7Medical Research Council MC_UU_00006/2Medical Research Council MC_UU_12015/1Medical Research Council MC_UU_12015/2Medical Research Council MR/T002239/1Wellcome Trust 204623/Z/16/Z
6 · The paper itself

Abstract

Testosterone supplementation is commonly used for its effects on sexual function, bone health and body composition, yet its effects on disease outcomes are unknown. To better understand this, we identified genetic determinants of testosterone levels and related sex hormone traits in 425,097 UK Biobank study participants. Using 2,571 genome-wide significant associations, we demonstrate that the genetic determinants of testosterone levels are substantially different between sexes and that genetically higher testosterone is harmful for metabolic diseases in women but beneficial in men. For example, a genetically determined 1 s.d. higher testosterone increases the risks of type 2 diabetes (odds ratio (OR) = 1.37 (95% confidence interval (95% CI): 1.22-1.53)) and polycystic ovary syndrome (OR = 1.51 (95% CI: 1.33-1.72)) in women, but reduces type 2 diabetes risk in men (OR = 0.86 (95% CI: 0.76-0.98)). We also show adverse effects of higher testosterone on breast and endometrial cancers in women and prostate cancer in men. Our findings provide insights into the disease impacts of testosterone and highlight the importance of sex-specific genetic analyses.

Indexed as

Biological Specimen BanksBiomarkersBody CompositionBreast NeoplasmsCluster AnalysisDiabetes Mellitus, Type 2Endometrial NeoplasmsEstradiolFemaleGenome-Wide Association StudyGenotypeHaplotypesHumansMaleMendelian Randomization AnalysisOdds RatioBiomarkersEstradiolTestosterone

Identifiers

PMID32042192
PMCPMC7025895
OpenAlexW3004892753

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.